Trial 3L-10-1

MR Techniques in the Evaluation of Hepatocellular Carcinoma: Gadoxetate.

Type: Screening/Diagnostic
Phase: Not Applicable
Status: Open to Accrual
Treatments:
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Gilbert Whang, M.D.
Other Trial Staff:

Staff may log in to see study documents.

You may participate in this study if:

	Requirement
1	CT features suggestive of HCC – For an arterially-enhancing lesion = / > 1 cm, but < 2 cm, all of the following criteria must be met: [1] Imaging features of a mass; [2] Wash-out on later phases of contrast administration; [3] At least 1 cm or more growth. For an arterially-enhancing leason = / > 2 cm, two of the following criteria must be met: [1] Imaging features of a mass; [2] Wash-out on later phases of contrast administration; [3] At least 1 cm or more growth.
2	At least 18 years of age
3	Able to tolerate a complete abdominal MR examination within 3 weeks of CT
4	Signed an approved study-specific informed consent and HIPAA

You may not participate in this study if:

1	Unable to undergo MRI due to intraocular metallic foreign body, pacemaker, or other contraindications including objects in the body which are deemed to be unsafe or notable to be assessed, or unable to undergo MRI within 3 weeks of CT
2	Prior history of treatment of liver lesions
3	Pregnancy
4	Severe renal insufficiency – estimated glomerular filtration rate of < 30 cc/min
5	Severe liver disease – Childs Class C Cirrhosis
6	History of a previous reaction to contrast media, bronchial asthma, or allergic disorders
7	Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the peri-operative liver transplantation period

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.